Altus Appoints Lynne H. Brum to its Board of Directors.Business Editors/Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 15, 2004 Altus(R) Biologics Inc. announced today that Lynne H. Brum has been appointed to its Board of Directors. Ms. Brum is an executive officer of Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. and a member of the Vertex Pharmaceuticals senior management team. "Lynne brings to Altus's Board a wealth of experience in the strategy and execution of initiatives that are vital to the success of innovative, high-growth companies," said Peter Lanciano, Chairman of the Board, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Altus. "As Altus transitions to focus on the development of multiple products for gastrointestinal and metabolic diseases, Lynne's strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. abilities and expertise in corporate communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. and finance will play a critical role in supporting our efforts." Ms. Brum is Vertex's Vice President of Corporate Communications and Financial Planning Financial planning Evaluating the investing and financing options available to a firm. Planning includes attempting to make optimal decisions, projecting the consequences of these decisions for the firm in the form of a financial plan, and then comparing future performance against . In this capacity, she leads the Company's financial planning group as well as its corporate communications, investor relations Investor relations The process by which the corporation communicates with its investors. and media relations initiatives. During her tenure at Vertex, she has held a variety of management positions in corporate communications, product marketing and corporate development. Ms. Brum has more than 16 years experience in the biotech industry leading the areas of investor relations, product communications, financial planning and financing. Ms. Brum joined Vertex in 1994 from Feinstein Kean Healthcare. Ms. Brum holds an M.B.A. from the Simmons Graduate School of Management, and a B.A. in biological sciences from Wellesley College. Altus is a pharmaceutical company that uses its proprietary protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. technology to develop innovative, orally delivered enzyme replacement therapies to treat a number of significant unmet medical needs in the areas of gastrointestinal and metabolic diseases. Altus' protein crystallization technology, known as Crystalomics(TM), enables the rapid commercialization of high-value orally delivered protein-based products by creating highly stable and potent protein therapeutics. The technology enables oral delivery of the protein to the gastrointestinal tract gastrointestinal tract n. The part of the digestive system consisting of the stomach, small intestine, and large intestine. Gastrointestinal tract to provide a localized or topical effect within the gastrointestinal lumen. These products are novel therapies that are designed to be safe, effective and convenient for patients. Through its product portfolio, the Company's vision is to be the worldwide leader in the rapid and efficient development of valuable oral enzyme replacement therapies for the treatment of gastrointestinal and metabolic diseases. The Company has a series of products in various stages of research and development, all leveraging the Crystalomics technology. Altus has numerous development partners and is constantly evaluating the opportunity to expand its product development efforts through partnering opportunities. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion